Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer
By Adam L. Cataldo
Merck said its blockbuster cancer drug Keytruda has been approved for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
The Food and Drug Administration approved the use of Keytruda, in combination with carboplatin and paclitaxel, to treat cancer patients based on data from a Phase 3 trial, Merck said Monday.
Keytruda in combination with the other drugs reduced the risk of disease progression or death by 40% in patients whose cancer was mismatch repair proficient, and by 70% in patients whose cancer was mismatch repair deficient, compared with a placebo.
The FDA's approval is the third endometrial carcinoma indication and the 40th indication overall for Keytruda in the U.S., Merck said.
Write to Adam Cataldo at adam.cataldo@wsj.com.
(END) Dow Jones Newswires
June 17, 2024 17:56 ET (21:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations